Navigation Links
Microbix Signs Marketing Agreement For Kinlytic(R)(Urokinase) In Growing Middle East Region
Date:11/17/2009

et forth in the forward-looking statements including the risks associated with failure to complete agreements to license, finance, develop and commercialize KINLYTIC on a timely basis, non-adoption of KINLYTIC, resistance to business model for commercialization and implementation; and risks associated with the efficacy of the drug. Risks related to timeliness, delay or failure to obtain local market regulatory approvals or to enter into marketing and supply agreements on acceptable terms or at all; risk of under-performance or non-performance by counter parties; accuracy of estimates of market and supply adequacy; ability to achieve market acceptance, sales and revenue generation on a timely basis or at all; product pricing risks; ability to fund from revenue or otherwise timely manufacturing scale up and to achieve manufacturing capacity, successful expansion of the drug into new indications and new markets. These forward-looking statements represent the Company's judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements.

SOURCE Microbix Biosystems Inc.


'/>"/>
SOURCE Microbix Biosystems Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Microbix Biosystems Re-files Annual Results With OSC
2. Microbix Biosystems Provides a Corporate Update
3. Microbix And Hunan Biopharmaceutical To Build Asias Largest Influenza Vaccine Facility
4. Microbix Sales Grow 22% For Nine Months
5. Microbix Files First Patent Applications On Novel Technology Platform For Large Semen Sexing Market
6. Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half 09
7. Microbix Announces A New Technology Platform For The SST Project
8. Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline
9. Microbix Uses Core Business Cashflow To Fund Late-Stage Pipeline To Build Shareholder Value In 2009
10. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
11. DATATRAK Signs New Client for Rescue Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... YORK , March 27, 2015  Peter Walter ... Biomedical Science for his pioneering work on how proteins ... components of a regulatory mechanism that cells use to ... Dr. Walter is a professor of biochemistry at the ... groundwork for treating a range of human diseases related ...
(Date:3/27/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE: ... technology platform company serving the global pharmaceutical, biotechnology, ... Investigational New Drug (IND) application for WuXi MedImmune,s ... been accepted for review by the China Food ... September 2012, MedImmune, the global biologics research and ...
(Date:3/27/2015)... Governor Andrew M. Cuomo today announced ... - the world’s largest business idea competition with $5 ... $1 million, six $500,000 awards and four $250,000 awards. ... compete for prizes that will turn ideas with high ... York region. , "Last year's successful 43North competition ...
(Date:3/26/2015)... 26, 2015 PRC Clinical, a Silicon-Valley ... several management and executive appointments effective immediately. , Mike ... (CFO) and member of the Board of Directors. Daniel ... and Sue Dowden will assume the position of Senior ... Chief Operations Officer (COO), has been appointed to the ...
Breaking Biology Technology:German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 2German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 3Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 2Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 3Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 4Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 5PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3
... Primary Endpoint in Second Phase III Trial in VMA, Confirms... -- LEUVEN, Belgium, September 1, 2010 ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
... SAN FRANCISCO, Aug. 31 Deloitte Recap recently ... pharmaceutical giant, Sanofi-aventis, and biotechnology firm, Exelixis, in ... which Exelixis gave Sanofi-aventis worldwide exclusive licenses for ... the development of PI3K inhibitor programs.  In exchange, ...
... the developers of PharmFilm® technology and a drug ... announced that its partner, Reckitt Benckiser Pharmaceuticals Inc., ... (LSE: RB), has received approval from the U.S. ... (buprenorphine HCl/naloxone HCl dihydrate) sublingual film for the ...
Cached Biology Technology:Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 2Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 3Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 4Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 5Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 6Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 7Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 8Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 9Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 10Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 11Deloitte Recap Honors Sanofi-aventis and Exelixis With the Allicense 2010 Breakthrough Alliance Award for Early-Stage Collaboration in Cancer 2MonoSol Rx Announces Reckitt Benckiser FDA Approval of Suboxone® Sublingual Film for Treatment of Opioid Dependence 2MonoSol Rx Announces Reckitt Benckiser FDA Approval of Suboxone® Sublingual Film for Treatment of Opioid Dependence 3
(Date:3/16/2015)... Between 16 and 20 ... innovations in biometric identification at the CeBIT exhibition ...      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ) , ... at the forefront: the company,s all new BiometricGate ... Germany . BiometricGate is the first ...
(Date:3/12/2015)... , March 12, 2015 The mascots ... Brenner Children,s Hospital, part of Wake Forest Baptist Medical ... initiative for the 2015 ACC Men,s Basketball Tournament. Young ... with them and getting their autographs. Brenner ... Baptist. It is the only children,s hospital in northwest ...
(Date:3/12/2015)... , March 12, 2015 WHEN:Tuesday, March 17, ... here: http://bit.ly/1G7Os0L . SPEAKERS: , Frost & ... - http://photos.prnewswire.com/prnh/20150311/181111 Biometric companies ... compete in several different markets and industries. This ... witnessing an uptrend. Join Frost ...
Breaking Biology News(10 mins):DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3
... by Dr. Jayne S. Weiss, Professor and Chair of Ophthalmology ... found that a defect in a gene involved in a ... of invasive bladder cancer. The findings are published in the ... Cell Biology . It is the featured research of the ...
... KANSAS CITY, MOAfter more than a century of study, mysteries ... cell division that helps insure genetic diversity in sexually-reproducing organisms. ... on an early and critical step in meiosis. The ... of Current Biology , clarifies the role of key ...
... The American Naturalist : The singer not ... global warming could cause animals to shrink How historic climate change ... to permanent problems For the complete table of contents ... The singer not the song: Why some birds think simple songs ...
Cached Biology News:Mutation in gene associated with rare eye disease also contributes to bladder cancer growth 2Pairing up: How chromosomes find each other 2Pairing up: How chromosomes find each other 3Why some birds think simple songs are sexy 2Why some birds think simple songs are sexy 3Why some birds think simple songs are sexy 4
Rat Aortic Smooth Muscle Cells (RAOSMC) (>500,000 cells)...
Rat Aortic Endothelial Cells (RAOEC) (>500,000 cells)...
... Model 440 incorporates four channels of sophisticated ... easy-to-use instrument. Each channel consists of a ... lowpass filter, a highpass filter, a line ... control knob sets the amplifier parameters and ...
... The H2OBIT™ is a fully licensed, high throughput, ... processing of up to 24 microplates. This equates ... plates. A robotic arm rapidly transfers ... resulting in temperature ramping times that are considerably ...
Biology Products: